Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib

PURPOSE: Vandetanib is well-tolerated in patients with advanced medullary thyroid carcinoma (MTC). Long-term outcomes and mechanisms of MTC progression have not been reported previously. DESIGN: We monitored toxicities and disease status in patients taking vandetanib for hereditary, advanced MTC. Tu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Kraft, Ira L, Akshintala, Srivandana, Zhu, Yuelin, Lei, Haiyan, Derse-Anthony, Claudia, Dombi, Eva, Steinberg, Seth M, Lodish, Maya, Waguespack, Steven G, Kapustina, Oxana, Fox, Elizabeth, Balis, Frank M, Merino, Maria J, Meltzer, Paul S, Glod, John W, Shern, Jack F, Widemann, Brigitte C
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815946/
https://ncbi.nlm.nih.gov/pubmed/29187393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2101
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים